SRRK [NASD]
Scholar Rock Holding Corporation
Index- P/E- EPS (ttm)-3.59 Insider Own1.60% Shs Outstand37.20M Perf Week-17.87%
Market Cap200.33M Forward P/E- EPS next Y-4.17 Insider Trans0.00% Shs Float31.35M Perf Month-47.42%
Income-131.80M PEG- EPS next Q-0.62 Inst Own93.20% Short Float16.18% Perf Quarter-69.05%
Sales18.80M P/S10.66 EPS this Y-27.60% Inst Trans0.41% Short Ratio10.87 Perf Half Y-85.15%
Book/sh4.63 P/B1.10 EPS next Y-13.60% ROA-40.70% Target Price44.40 Perf Year-81.28%
Cash/sh6.44 P/C0.79 EPS next 5Y- ROE-64.60% 52W Range4.93 - 44.95 Perf YTD-79.47%
Dividend- P/FCF- EPS past 5Y-40.20% ROI-58.50% 52W High-88.21% Beta0.64
Dividend %- Quick Ratio4.10 Sales past 5Y118.40% Gross Margin- 52W Low7.41% ATR0.86
Employees145 Current Ratio4.10 Sales Q/Q17.60% Oper. Margin- RSI (14)31.66 Volatility17.39% 12.22%
OptionableYes Debt/Eq0.29 EPS Q/Q-23.30% Profit Margin- Rel Volume1.23 Prev Close5.10
ShortableYes LT Debt/Eq0.28 EarningsMay 16 AMC Payout- Avg Volume466.37K Price5.30
Recom2.00 SMA20-20.86% SMA50-47.76% SMA200-77.05% Volume74,843 Change3.92%
Mar-23-22Initiated H.C. Wainwright Buy $24
Dec-22-21Downgrade Jefferies Buy → Hold $52 → $28
Nov-19-21Initiated Piper Sandler Overweight $56
Apr-26-21Resumed Credit Suisse Outperform $65
Jan-11-21Initiated Credit Suisse Outperform $65
Jan-06-21Initiated JP Morgan Overweight $59
Mar-12-20Initiated Robert W. Baird Outperform $35
May-17-22 02:49PM  
12:33PM  
May-16-22 04:15PM  
May-10-22 08:05AM  
Apr-21-22 07:30AM  
Mar-24-22 09:29AM  
Mar-22-22 07:30AM  
Mar-17-22 01:54PM  
Mar-14-22 08:32AM  
Mar-13-22 07:00PM  
Mar-07-22 08:15AM  
07:00AM  
Mar-01-22 03:00PM  
Feb-25-22 07:30AM  
Feb-08-22 12:54PM  
Jan-25-22 08:30AM  
Jan-10-22 07:30AM  
Jan-04-22 04:01PM  
Nov-30-21 04:05PM  
Nov-16-21 10:28AM  
Nov-12-21 07:05AM  
Nov-09-21 09:15AM  
08:05AM  
Nov-02-21 04:01PM  
Nov-01-21 03:01PM  
Oct-05-21 12:18PM  
Oct-03-21 08:00AM  
Sep-30-21 11:45AM  
Sep-29-21 02:28PM  
Sep-28-21 04:01PM  
Sep-23-21 11:31AM  
Sep-22-21 04:01PM  
Aug-17-21 07:40PM  
Aug-16-21 04:05PM  
Aug-15-21 12:00PM  
Aug-13-21 10:07PM  
Aug-11-21 11:43PM  
Aug-10-21 07:15PM  
04:15PM  
06:52AM  
Aug-09-21 08:39PM  
Aug-07-21 02:00PM  
Aug-05-21 08:21PM  
04:01PM  
Aug-03-21 10:55PM  
07:30AM  
Jul-30-21 03:00PM  
Jun-18-21 08:00AM  
Jun-11-21 07:30AM  
Jun-07-21 07:30AM  
May-27-21 08:01AM  
May-24-21 04:05PM  
May-19-21 05:05PM  
May-13-21 12:11PM  
07:30AM  
May-12-21 07:33AM  
May-11-21 04:30PM  
Apr-29-21 12:34PM  
Apr-26-21 04:59PM  
Apr-24-21 09:45PM  
Apr-21-21 08:37PM  
05:22PM  
Apr-19-21 11:17PM  
Apr-16-21 10:23PM  
Apr-14-21 11:57PM  
Apr-13-21 06:56AM  
06:25AM  
Apr-11-21 04:00AM  
Apr-10-21 08:30AM  
Apr-06-21 12:17PM  
07:48AM  
07:00AM  
Mar-22-21 04:20PM  
Mar-18-21 04:05PM  
Mar-17-21 04:05PM  
Mar-15-21 08:00AM  
Mar-09-21 05:45PM  
04:05PM  
Mar-04-21 12:30PM  
Feb-04-21 04:30PM  
Jan-27-21 08:00AM  
Jan-11-21 07:30AM  
Jan-04-21 04:01PM  
Dec-03-20 06:21PM  
Nov-29-20 11:41AM  
Nov-13-20 08:38AM  
Nov-12-20 08:00AM  
Nov-09-20 02:47PM  
08:00AM  
Nov-04-20 07:24AM  
Nov-02-20 04:05PM  
Oct-28-20 10:33PM  
10:24AM  
Oct-27-20 04:17PM  
10:46AM  
07:00AM  
Oct-19-20 07:30AM  
Sep-30-20 07:30AM  
Sep-09-20 07:30AM  
Sep-04-20 03:58PM  
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myles Edward HChief Financial OfficerNov 15Sale35.054,879171,00624,150Nov 15 09:28 PM
Myles Edward HChief Financial OfficerNov 12Sale35.1249,8481,750,43724,150Nov 15 09:28 PM
Myles Edward HChief Financial OfficerNov 11Sale35.2023,574829,85724,150Nov 15 09:28 PM
FLIER JEFFREY S.DirectorOct 01Sale30.896,000185,32922,272Oct 05 08:15 AM
FLIER JEFFREY S.DirectorSep 20Sale34.0950017,0459,013Sep 21 04:46 PM
FLIER JEFFREY S.DirectorJul 26Sale31.666,000189,95428,272Jul 28 04:17 PM